Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells.

Rodrigues NV, Correia DV, Mensurado S, Nóbrega-Pereira S, deBarros A, Kyle-Cezar F, Tutt A, Hayday AC, Norell H, Silva-Santos B, Dias S.

Cancer Immunol Res. 2018 Apr;6(4):448-457. doi: 10.1158/2326-6066.CIR-17-0327. Epub 2018 Jan 22.

2.

Uncoupling between immunological synapse formation and functional outcome in human gamma delta T lymphocytes.

Favier B, Espinosa E, Tabiasco J, Dos Santos C, Bonneville M, Valitutti S, Fournié JJ.

J Immunol. 2003 Nov 15;171(10):5027-33.

3.

Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.

Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls MH, Lee DA, Bast RC Jr, Champlin RE, Cooper LJ.

Clin Cancer Res. 2014 Nov 15;20(22):5708-19. doi: 10.1158/1078-0432.CCR-13-3451. Epub 2014 May 15.

4.

Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.

Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, Caignard A.

J Immunol. 2005 Feb 1;174(3):1338-47.

5.

CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.

Poccia F, Cipriani B, Vendetti S, Colizzi V, Poquet Y, Battistini L, López-Botet M, Fournié JJ, Gougeon ML.

J Immunol. 1997 Dec 15;159(12):6009-17.

PMID:
9550399
6.

Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.

Bouet-Toussaint F, Cabillic F, Toutirais O, Le Gallo M, Thomas de la Pintière C, Daniel P, Genetet N, Meunier B, Dupont-Bierre E, Boudjema K, Catros V.

Cancer Immunol Immunother. 2008 Apr;57(4):531-9. Epub 2007 Sep 1.

PMID:
17764010
8.

NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals.

Nedellec S, Sabourin C, Bonneville M, Scotet E.

J Immunol. 2010 Jul 1;185(1):55-63. doi: 10.4049/jimmunol.1000373. Epub 2010 May 28.

9.

Complex interplay of activating and inhibitory signals received by Vgamma9Vdelta2 T cells revealed by target cell beta2-microglobulin knockdown.

Trichet V, Benezech C, Dousset C, Gesnel MC, Bonneville M, Breathnach R.

J Immunol. 2006 Nov 1;177(9):6129-36.

10.

Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.

Di Carlo E, Bocca P, Emionite L, Cilli M, Cipollone G, Morandi F, Raffaghello L, Pistoia V, Prigione I.

Mol Ther. 2013 May;21(5):1034-43. doi: 10.1038/mt.2013.38. Epub 2013 Mar 12.

11.

In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.

Benzaïd I, Mönkkönen H, Bonnelye E, Mönkkönen J, Clézardin P.

Clin Cancer Res. 2012 Nov 15;18(22):6249-59. doi: 10.1158/1078-0432.CCR-12-0918. Epub 2012 Oct 2.

12.

Cytokine-mediated activation of human ex vivo-expanded Vγ9Vδ2 T cells.

Domae E, Hirai Y, Ikeo T, Goda S, Shimizu Y.

Oncotarget. 2017 Jul 11;8(28):45928-45942. doi: 10.18632/oncotarget.17498.

13.

Aminobisphosphonates Synergize with Human Cytomegalovirus To Activate the Antiviral Activity of Vγ9Vδ2 Cells.

Daguzan C, Moulin M, Kulyk-Barbier H, Davrinche C, Peyrottes S, Champagne E.

J Immunol. 2016 Mar 1;196(5):2219-29. doi: 10.4049/jimmunol.1501661. Epub 2016 Jan 27.

14.

CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.

Dessarthe B, Thedrez A, Latouche JB, Cabillic F, Drouet A, Daniel P, de La Pintière CT, Catros V, Toutirais O.

J Immunol. 2013 May 1;190(9):4868-76. doi: 10.4049/jimmunol.1202596. Epub 2013 Mar 25.

15.

Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.

Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M.

Blood. 2011 Sep 22;118(12):3301-10. doi: 10.1182/blood-2011-02-336321. Epub 2011 Aug 5.

PMID:
21821703
16.

Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer.

Lesport E, Baudhuin J, Sousa S, LeMaoult J, Zamborlini A, Rouas-Freiss N, Carosella ED, Favier B.

Cell Mol Life Sci. 2011 Oct;68(20):3385-99. doi: 10.1007/s00018-011-0632-7. Epub 2011 Feb 20. Erratum in: Cell Mol Life Sci. 2011 Oct;68(20):3401.

PMID:
21337044
17.

IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.

Thedrez A, Harly C, Morice A, Salot S, Bonneville M, Scotet E.

J Immunol. 2009 Mar 15;182(6):3423-31. doi: 10.4049/jimmunol.0803068.

18.

Opportunities and challenges in development of phosphoantigens as Vγ9Vδ2 T cell agonists.

Wiemer DF, Wiemer AJ.

Biochem Pharmacol. 2014 Jun 1;89(3):301-12. doi: 10.1016/j.bcp.2014.03.009. Epub 2014 Mar 26.

PMID:
24680696
19.

Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.

Correia DV, d'Orey F, Cardoso BA, Lança T, Grosso AR, deBarros A, Martins LR, Barata JT, Silva-Santos B.

PLoS One. 2009 May 21;4(5):e5657. doi: 10.1371/journal.pone.0005657.

20.

DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.

Toutirais O, Cabillic F, Le Friec G, Salot S, Loyer P, Le Gallo M, Desille M, de La Pintière CT, Daniel P, Bouet F, Catros V.

Eur J Immunol. 2009 May;39(5):1361-8. doi: 10.1002/eji.200838409.

Supplemental Content

Support Center